Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report-Reference-Cited by-同舟云学术

Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report

Published:2020-07 Issue:1 Volume:76 Page:144-147
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Phadke Gautam,Kaushal Amit,Tolan Dean R.,Hahn Kai,Jensen Thomas,Bjornstad Petter,Roncal-Jimenez Carlos,Hernando Ana Andres,Lanaspa Miguel A.,Alexander Mariam Priya,Kukla Aleksandra,Johnson Richard J.

Funder

Horizon Pharma

Publisher

Elsevier BV

Subject

Nephrology

Reference19 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors;Weir;Postgrad Med,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis;Frontiers in Pharmacology;2024-06-25

2. Combination therapy for kidney disease in people with diabetes mellitus;Nature Reviews Nephrology;2024-04-03

3. Impact of Dapagliflozin on the Renal Function and Damage in Patients with Heart Failure with a Reduced Ejection Fraction;Internal Medicine;2024-01-15

4. Drug-induced nephrotoxicity and its biomarkers;Essentials of Pharmatoxicology in Drug Research, Volume 1;2023

5. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor;Internal Medicine;2022-11-01